Search

Your search keyword '"Shokouhi, Shervin"' showing total 211 results
Start Over Author "Shokouhi, Shervin"
211 results on '"Shokouhi, Shervin"'

3. Liposomal amphotericin for secondary prophylaxis: A systematic review and meta-analysis.

Author

Javandoust Gharehbagh, Farid, Roshanzamiri, Soheil, Farjami, Mohammad, Hatami, Firouze, Lotfollahi, Legha, Kazeminia, Neda, Hatami, Fatemeh, Shokouhi, Shervin, and Alavi Darazam, Ilad

Subjects
MYCOSES, ANTIFUNGAL agents, PATIENT safety, META-analysis, DESCRIPTIVE statistics, SYSTEMATIC reviews, HYPOKALEMIA, AMPHOTERICIN B, DRUG efficacy, ANTIBIOTIC prophylaxis, KIDNEY diseases
Abstract

Introduction: This systematic review and meta-analysis aimed to determine the safety of liposomal amphotericin B (L-AMB) compared to other antifungal agents for secondary prophylaxis. Method: We conducted a comprehensive search across international databases and reference lists of articles to compile all relevant published evidence evaluating the efficacy and safety of L-AMB versus other antifungals (NLAMB) for secondary prophylaxis against invasive fungal infections. Pooled estimates were calculated after data transformation to evaluate mortality, breakthrough infections, and the frequency of adverse effects, including hypokalemia and nephrotoxicity. Comparisons of breakthrough fungal infection and mortality between the L-AMB and NLAMB groups were performed. Result: We identified 10 studies. The cumulative frequency of patients using L-AMB was 148, compared to 341 patients in the NLAMB group. The mortality rates in the L-AMB and NLAMB groups were 10% and 0%, respectively. However, based on the odds ratio, the mortality in the L-AMB group was lower than that in the NLAMB group. No significant difference was observed in breakthrough invasive fungal infections between the L-AMB and NLAMB groups. The frequencies of nephropathy and hypokalemia in the L-AMB group were 36% and 18%, respectively. Conclusion: Our findings indicate a lower incidence of mortality in the L-AMB group compared to the NLAMB group. No statistically significant difference was observed in the incidence of breakthrough infection between the two groups. L-AMB administration is associated with nephropathy and hypokalemia. However, the refusal to continue treatment due to adverse effects is not significantly high. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Mucormycosis, New Causative Agents, and New Susceptible Populations: Review of Cases in a Tertiary Care Hospital in Iran (2007-2021)

Author

Darazam, Ilad Alavi, primary, Babamahmoodi, Abdolreza, additional, Ebrahimi, Mohammad Javad, additional, Moafi, Maral, additional, Dilmaghani, Nader Akbari, additional, Mardani, Masoud, additional, Shokouhi, Shervin, additional, Gharehbagh, Farid Javandoust, additional, Chalmiani, Elmira Mahmoudi, additional, Shabani, Meinoosh, additional, Bidari, Farahnaz, additional, Jamali, Elena, additional, Khoshsirat, Shahrokh, additional, Shahriari, Mansoor, additional, Sabeti, Shahram, additional, Rahmani, Zahra, additional, Mousavinejad, Seyed Ali, additional, Ebrahimzadeh, Kaveh, additional, and Hallajnejad, Mohammad, additional

Published
2023
Full Text
View/download PDF

8. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial

Author

Alavi Darazam, Ilad, Shokouhi, Shervin, Pourhoseingholi, Mohamad Amin, Naghibi Irvani, Seyed Sina, Mokhtari, Majid, Shabani, Minoosh, Amirdosara, Mahdi, Torabinavid, Parham, Golmohammadi, Maryam, Hashemi, SayedPayam, Azimi, Arsalan, Jafarazadeh Maivan, Mohammad Hossein, Rezaei, Omidvar, Zali, Alireza, Hajiesmaeili, Mohammadreza, Shabanpour Dehbsneh, Hadiseh, Hoseyni Kusha, Akram, Taleb Shoushtari, Maryam, Khalili, Negar, Soleymaninia, Azam, Gachkar, Latif, and Khoshkar, Ali

Published
2021
Full Text
View/download PDF

11. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial

Author

Alavi Darazam, Ilad, Hatami, Firouze, Rabiei, Mohammad Mahdi, Pourhoseingholi, Mohamad Amin, Moradi, Omid, Shokouhi, Shervin, Hajesmaeili, Mohammad Reza, Shabani, Minoosh, and Irvani, Seyed Sina Naghibi

Published
2020
Full Text
View/download PDF

16. Efficacy of Hemoperfusion in Severe and Critical Cases of COVID-19

Author

Alavi Darazam, Ilad, primary, Kazempour, Muhanna, additional, Pourhoseingholi, Mohamad Amin, additional, Hatami, Firouze, additional, Rabiei, Mohammad Mahdi, additional, Javandoust Gharehbagh, Farid, additional, Amirdosara, Mahdi, additional, Hajiesmaeili, Mohammadreza, additional, Shabani, Minoosh, additional, Shokouhi, Shervin, additional, Lotfollahi, Legha, additional, Mardani, Masoud, additional, Haghighi-Morad, Maryam, additional, Nassiri, Amir Ahmad, additional, Rangraz, Davoud, additional, Falahaty, Hassan, additional, Syami, Hosein, additional, Irannejad, Yaghoob, additional, Fallah, Maryam, additional, Zangi, Masoud, additional, and Shafigh, Navid, additional

Published
2022
Full Text
View/download PDF

20. Clinical Aspects, Microbiological Features, and Therapeutic Outcome of Brain Abscess: An Experience of a Referral Center

Author

Darazam, Ilad Alavi, primary, Hatami, Firouze, additional, Shokouhi, Shervin, additional, Mardani, Masoud, additional, Shabani, Minoosh, additional, Khabiri, Neda, additional, Rezaei, Omidvar, additional, Gharehbagh, Farid Javandoust, additional, Samadian, Mohammad, additional, Sharifi, Guive, additional, Ebrahimzadeh, Kaveh, additional, Mousavinejad, Seyed Ali, additional, Hallajnejad, Mohammad, additional, Rabiei, Mohammad Mahdi, additional, Bidari, Farahnaz, additional, Jamali, Elena, additional, and Sabeti, Shahram, additional

Published
2022
Full Text
View/download PDF

22. Study of the effects of interferon β−1a on hospitalized patients with COVID‐19: SBMU Taskforce on the COVIFERON study

Author

Fallahzadeh, Mohammad, primary, Pourhoseingholi, Mohamad A., additional, Boroujeni, Masoud G., additional, Besharati, Sajad, additional, Mardani, Masoud, additional, Shabani, Minoosh, additional, Shokouhi, Shervin, additional, Amirdosara, Mahdi, additional, Hajiesmaeili, Mohammadreza, additional, Gachkar, Latif, additional, Roshan, Baran, additional, Zangi, Masoud, additional, Mirmomeni, Golshan, additional, Irvani, Seyed S. N., additional, and Alavi Darazam, Ilad, additional

Published
2021
Full Text
View/download PDF

23. Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)

Author

Mobarak, Sara, primary, Salasi, Mehdi, additional, Hormati, Ahmad, additional, Khodadadi, Javad, additional, Ziaee, Masood, additional, Abedi, Farshid, additional, Ebrahimzadeh, Azadeh, additional, Azarkar, Zohreh, additional, Mansour-Ghanaei, Fariborz, additional, Joukar, Farahnaz, additional, Yeganeh, Sara, additional, Yaghubi Kalurazi, Tofigh, additional, Naghipour, Mohammadreza, additional, Mehrabi, Zeinab, additional, Bahadori, Amir Reza, additional, Yaghoubi, Shoeleh, additional, Moslemi, Rohollah, additional, Abbaspour Kasgari, Hamideh, additional, Fakheri, Hafez, additional, Moghimi, Minoo, additional, Shabani, Amir Mohammad, additional, Nekoukar, Zahra, additional, Babamahmoodi, Farhang, additional, Davoudi Badabi, Ali Reza, additional, Davoodi, Lotfollah, additional, Hassaniazad, Mehdi, additional, Barahimi, Elham, additional, Tousi, Abdolali, additional, Sadeghi, Anahita, additional, Hosamirudsari, Hadiseh, additional, Ali Asgari, Ali, additional, Abdollahi, Mohammad, additional, Anushiravani, Amir, additional, Shabani, Minoosh, additional, Shokouhi, Shervin, additional, Khajavirad, Nasim, additional, Salehi, Mohammadreza, additional, Dehghan Manshadi, Seyed Ali, additional, Mousavi, Hashem, additional, Zolfaghari, Farnaz, additional, Azimi, Elmira, additional, Zeinali, Aida, additional, Akbarpour, Elham, additional, Merat, Dorsa, additional, Eslami, Gholamali, additional, Mousaviasl, Sajedeh, additional, Sayar, Sara, additional, Radmanesh, Esmat, additional, Ebrahimzadeh, Mona, additional, Arizavi, Zahra, additional, Jelvay, Saeed, additional, Salmanzadeh, Shokrollah, additional, Esmaeilian, Hani, additional, Mobarak, Morteza, additional, Karimi, Jalal, additional, Poormontaseri, Zahra, additional, Hasooni Bahrini, Nasrollah, additional, Bonyadi, Atefeh, additional, Dehghani, Fatemeh, additional, Mirzaei, Hadi, additional, Noori Jangi, Masoome, additional, Pourmasoomi, Hossein, additional, Rezaie Keikhaie, Lili, additional, Afshari, Mahdi, additional, Nateghi Baygi, Alireza, additional, Nateghi Baygi, Helia, additional, Levi, Jacob, additional, McCann, Kaitlyn, additional, Wentzel, Hannah, additional, Simmons, Bryony, additional, Hill, Andrew, additional, and Merat, Shahin, additional

Published
2021
Full Text
View/download PDF

24. Efficacy of Hemoperfusion in Severe and Critical Cases of COVID-19.

Author

Alavi Darazam, Ilad, Kazempour, Muhanna, Pourhoseingholi, Mohamad Amin, Hatami, Firouze, Rabiei, Mohammad Mahdi, Javandoust Gharehbagh, Farid, Amirdosara, Mahdi, Hajiesmaeili, Mohammadreza, Shabani, Minoosh, Shokouhi, Shervin, Lotfollahi, Legha, Mardani, Masoud, Haghighi-Morad, Maryam, Nassiri, Amir Ahmad, Rangraz, Davoud, Falahaty, Hassan, Syami, Hosein, Irannejad, Yaghoob, Fallah, Maryam, and Zangi, Masoud

Subjects
HEMOPERFUSION, COVID-19 pandemic, COVID-19, RENAL replacement therapy
Abstract

Introduction: Uncontrolled overproduction of inflammatory mediators is predominantly observed in patients with severe COVID-19. The excessive immune response gives rise to multiple organ dysfunction. Implementing extracorporeal therapies may be useful in omitting inflammatory mediators and supporting different organ systems. We aimed to investigate the effectiveness of hemoperfusion in combination with standard therapy in critically ill COVID-19 patients. Method: We conducted a single-center, matched control retrospective study on patients with confirmed SARS-CoV-2 infection. Patients were treated with hemoperfusion in combination with standard therapy (hemoperfusion group) or standard treatment (matched group). Hemoperfusion or hemoperfusion and continuous renal replacement therapies were initiated in the hemoperfusion group. The patients in the matched group were matched one by one with the hemoperfusion group for age, sex, oxygen saturation (SPO2) at the admission, and the frequency of using invasive mechanical ventilation during hospitalization. Two types of hemoperfusion cartridges used in this study were Jafron© (HA330) and CytoSorb® 300. Result: A total of 128 COVID-19-confirmed patients were enrolled in this study; 73 patients were allotted to the matched group and 55 patients received hemoperfusion. The median SPO2 at the admission day in the control and hemoperfusion groups was 80% and 75%, respectively (p value = 0.113). The mortality rate was significantly lower in the hemoperfusion group compared to the matched group (67.3% vs. 89%; p value = 0.002). The median length of ICU stay was statistically different in studied groups (median, 12 days for hemoperfusion group vs. 8 days for the matched group; p < 0.001). The median final SPO2 was statistically higher in the hemoperfusion group than in the matched group, and the median PaCO2 was lower. Conclusion: Among critically ill COVID-19 patients, based on our study, the use of hemoperfusion may reduce the mortality rate and improve SPO2 and PaCO2. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial

Author

Alavi Darazam, Ilad, primary, Hatami, Firouze, additional, Mahdi Rabiei, Mohammad, additional, Amin Pourhoseingholi, Mohamad, additional, Shabani, Minoosh, additional, Shokouhi, Shervin, additional, Mardani, Masoud, additional, Moradi, Omid, additional, Javandoust Gharehbagh, Farid, additional, Mirtalaee, Nasrinsadat, additional, Negahban, Halimeh, additional, Amirdosara, Mahdi, additional, Zangi, Masoud, additional, Hajiesmaeili, Mohammadreza, additional, Kazempour, Muhanna, additional, and Shafigh, Navid, additional

Published
2021
Full Text
View/download PDF

29. Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-19

Author

Shabani, Minoosh, primary, Totonchi, Mehdi, additional, Rezaeimirghaed, Omidvar, additional, Gachkar, Latif, additional, Hajiesmaeili, Mohammadreza, additional, Khoshkar, Ali, additional, Amirdosara, Mahdi, additional, Saffaei, Ali, additional, Shokouhi, Shervin, additional, Mardani, Masoud, additional, Alavi Darazam, Ilad, additional, Karami, Alireza, additional, Sharifi, Milad, additional, Zaman, Mana, additional, Abedheydari, Elham, additional, and Sahraei, Zahra, additional

Published
2021
Full Text
View/download PDF

30. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial

Author

Alavi Darazam, Ilad, primary, Shokouhi, Shervin, additional, Mardani, Masoud, additional, Pourhoseingholi, Mohamad Amin, additional, Rabiei, Mohammad Mahdi, additional, Hatami, Firouze, additional, Shabani, Minoosh, additional, Moradi, Omid, additional, Gharehbagh, Farid Javandoust, additional, Irvani, Seyed Sina Naghibi, additional, Amirdosara, Mahdi, additional, Hajiesmaeili, Mohammadreza, additional, Rezaei, Omidvar, additional, Khoshkar, Ali, additional, Lotfollahi, Legha, additional, Gachkar, Latif, additional, Dehbsneh, Hadiseh Shabanpour, additional, Khalili, Negar, additional, Soleymaninia, Azam, additional, Kusha, Akram Hoseyni, additional, Shoushtari, Maryam Taleb, additional, and Torabinavid, Parham, additional

Published
2021
Full Text
View/download PDF

36. Efficacy of Hemoperfusion in Severe and Critical Cases of COVID-19

Author

Darazam, Ilad Alavi, primary, Kazempour, Muhanna, additional, Pourhoseingholi, Mohamad Amin, additional, Hatami, Firouze, additional, Rabiei, Mohammad Mahdi, additional, Gharehbagh, Farid Javandoust, additional, Amirdosara, Mahdi, additional, Hajiesmaeili, Mohammadreza, additional, Shabani, Minoosh, additional, Shokouhi, Shervin, additional, Lotfollahi, Legha, additional, Mardani, Masoud, additional, Haghighi-Morad, Maryam, additional, Rangraz, Davoud, additional, Falahaty, Hassan, additional, Syami, Hosein, additional, Irannejad, Yaghoob, additional, fallah, Maryam, additional, Zangi, Masoud, additional, and Shafigh, Navid, additional

Published
2021
Full Text
View/download PDF

38. Efficacy of Interferon β-1a in Treatment of Hospitalized COVID-19 Patients; SBMU Taskforce on the COVIFERON Study

Author

Fallahzadeh, Mohammad, primary, Pourhoseingholi, Mohamad Amin, additional, Besharati, Sajad, additional, Boroujeni, Masoud Ghanbari, additional, Mardani, Masoud, additional, Shabani, Minoosh, additional, Shokouhi, Shervin, additional, Amirdosara, Mahdi, additional, Hajiesmaeili, Mohammadreza, additional, Gachkar, Latif, additional, Roshan, Baran, additional, Zangi, Masoud, additional, Mirmomeni, Golshan, additional, Irvani, Seyed Sina Naghibi, additional, and Darazam, Ilad Alavi, additional

Published
2021
Full Text
View/download PDF

39. Emergence of carbapenem resistant Acinetobacter baumannii clonal complexes CC2 and CC10 among fecal carriages in an educational hospital.

Author

Nazari, Mohsen, Azizi, Omid, Solgi, Hamid, Fereshteh, Sepideh, Shokouhi, Shervin, and Badmasti, Farzad

Subjects
ACINETOBACTER infections, ACADEMIC medical centers, FECES, CARBAPENEMS
Abstract

Carbapenem-resistant Acinetobacter baumannii strains are increasing worldwide. In this study, samples were collected from hospital environments, extra hospital environments, and fecal carriages. 76% (89/117) of bacterial isolates were detected as A. baumannii strains. The imipenem resistance in the hospital environment, fecal carriages, extra hospital environments, and clinical isolates was 37.7% (17/45), 100% (9/9), 0% (0/45), and 92.9% (92/99), respectively. The blaVIM and blaOXA-23 were detected in 6.6% (3/45) and 2.2% (1/45) of strains isolated from hospital environments. Interestingly, strains isolated from fecal carriages had blaVIM, blaOXA-23, and blaIMP genes which resembled carbapenem resistance genes in clinical strains. The structure of clonal relatedness among all non-clinical isolates was as follows: CC2, 37% (33/89); CC1, 22.4% (20/89); CC3, 12.3% (11/89); CC25, 7.8% (7/89); CC10, 4.4% (4/89) and CC15, 2.2% (2/89). Comparison of clonal relatedness among clinical and non-clinical isolates indicated that widespread clones including CC2, CC3, and CC10 were common clonal complexes between two categories. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. The global prevalence of Chlamydia pneumoniae, Helicobacter pylori, Cytomegalovirus and Herpes simplex virus in patients with coronary artery disease: A systematic review and meta-analysis

Author

Dadashi, Masoud, primary, Hajikhani, Bahareh, additional, Ghazi, Mona, additional, Yazdani, Shahrooz, additional, Goudarzi, Mehdi, additional, Nasiri, Mohammad Javad, additional, Shokouhi, Shervin, additional, Owlia, Parviz, additional, and Yaslianifard, Somayeh, additional

Published
2021
Full Text
View/download PDF

43. Antipseudomonal β-Lactams Resistance in Iran

Author

Rabiei, Mohammad Mahdi, Asadi, Keivan, Shokouhi, Shervin, Nasiri, Mohammad Javad, and Alavi Darazam, Ilad

Subjects
Article Subject, polycyclic compounds
Abstract

Over the last years, the mortality rate of Pseudomonas aeruginosa, which is one of the major reasons for severe infections, has been significantly increasing. This bacterium is highly resistant to many antibiotics, especially carbapenems, thanks to its complicated mechanism by which it can acquire exogenous genes. The purpose of this research is to have a review of empirical studies surveying the P. aeruginosa resistance to beta-lactams in Iran in order to investigate the most reliable methods by which the incidence of P. aeruginosa infections can be decreased and controlled. We performed a systematic review of all articles published from 2008 until 2018. Studies which did not address P. aeruginosa resistance to beta-lactams were excluded from the analysis. Studies with less than 10 cases were also excluded. Studies with more than ten cases, which did not have repetitive information, were taken into account for the final selection; 133 out of 893 articles were chosen. The resistance rate of P. aeruginosa among the articles was as follows: more than 72% of studies revealed >50% level of resistance to cefepime, followed by aztreonam (53.2%), ceftazidime (61%), piperacillin/tazobactam (54.5%), meropenem (48.3%), and imipenem (42.4%). The selection of empiric antipseudomonal antibiotics is absolutely uncertain and hazardous, and the risk of clinical failure may be more among cephalosporins and piperacillin-tazobactam as well as aztreonam. The results of this study illustrate that the methods enabling clinics to identify the bacterium resistance pattern and its genetic basis and to have the opportunity of empiric therapies through access to updated local data of antimicrobial susceptibility pattern are the most effective methods. However, the widespread usage of these approaches undoubtedly needs reliable molecular and nucleic acid-based devices, which are both affordable and available.

Published
2020
Full Text
View/download PDF

44. Is a Low Incidence Rate of Ventilation Associated Pneumonia Associated with Lower Mortality? a Descriptive Longitudinal Study in Iran

Author

Chouhdari, Arezoo, Shokouhi, Shervin, Bashar, Farshid Rahimi, Vahedian Azimi, Amir, Shojaei, Seyed Pouzhia, Fathi, Mohammad, Goharani, Reza, Sahraei, Zahra, and Hajiesmaeili, Mohammadreza

Subjects
Case fatality rate, Attributable mortality rate, Cost, Incidence, ICU, VAP, Original Article, respiratory tract diseases
Abstract

Background: Ventilator-Associated Pneumonia (VAP) is an important cause of morbidity and mortality in patients admitted to Intensive Care Unit (ICU). The current study conducted to estimate VAP incidence, attributable mortality and case fatality rate, cost, so related factors can affect the outcome in patients. Materials and Methods: In this descriptive longitudinal study, demographic, clinical and para-clinical data were collected and attributable mortality and case fatality rate was estimated. Multivariable analysis was done to predict the possible risk factors on the outcome of VAP patients. Also, patients’ survival curve was plotted based on their length of ICU stay. Finally, the additional cost due to VAP in ICU was estimated. Results: Totally, 8% ICU admissions were affected by VAP and 4% expired during the ICU stay. Further, the attributable mortality rate of VAP was high as compared with standard mortality rate. The most case fatality rate was for Acinetobacter sp. (n=17 60.7%). In multivariable logistic regression analysis, age greater than 40 years, more than 96 hours mechanical ventilation and uncontrolled diabetes mellitus were predictor factors of higher mortality. Inverse association between survival time and ICU length of stay was reported. Finally, the additional cost of VAP was estimated of about 700 US$ per patients. Conclusion: According to the results, strategies to prevent mortality by reducing the duration of ventilation and ICU length of stay should be performed. Also, mandatory fees for the family and the healthcare system should be planned.

Published
2018

45. An Investigation Into the Beneficial Effects of High-Dose Interferon beta 1-a, Compared to Low-Dose Interferon Beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19

Author

Darazam, Ilad Alavi, primary, Hatami, Firouze, additional, Rabiei, Mohammad Mahdi, additional, Pourhoseingholi, Mohamad Amin, additional, Shabani, Minoosh, additional, Shokouhi, Shervin, additional, Moradi, Omid, additional, Gharehbagh, Farid Javandoust, additional, Mirtalaee, Nasrinsadat, additional, Negahban, Halimeh, additional, Amirdosara, Mahdi, additional, Zangi, Masoud, additional, Hajiesmaeili, Mohammadreza, additional, Kazempour, Muhanna, additional, and Shafigh, Navid, additional

Published
2021
Full Text
View/download PDF

46. Role of Interferon Therapy in Severe COVID-19: The COVIFERON Randomized Controlled Trial

Author

Darazam, Ilad Alavi, primary, Pourhoseingholi, Mohamad Amin, additional, Shokouhi, Shervin, additional, Irvani, Seyed Sina Naghibi, additional, Mokhtari, Majid, additional, Shabani, Minoosh, additional, Amirdosara, Mahdi, additional, Torabinavid, Parham, additional, Golmohammadi, Maryam, additional, Hashemi, SayedPayam, additional, Azimi, Arsalan, additional, Maivan, Mohammad Hossein Jafarzadeh, additional, Rezaeimirghaed, Omidvar, additional, Zali, Alireza, additional, Hajiesmaeili, Mohammadreza, additional, Dehbsneh, Hadiseh Shabanpour, additional, Kusha, Akram Hoseyni, additional, Shoushtari, Maryam Taleb, additional, Khalili, Negar, additional, Soleymaninia, Azam, additional, Gachkar, Latif, additional, and Khoshkar, Ali, additional

Published
2021
Full Text
View/download PDF

50. Study of the effects of interferon β−1a on hospitalized patients with COVID‐19: SBMU Taskforce on the COVIFERON study.

Author

Fallahzadeh, Mohammad, Pourhoseingholi, Mohamad A., Boroujeni, Masoud G., Besharati, Sajad, Mardani, Masoud, Shabani, Minoosh, Shokouhi, Shervin, Amirdosara, Mahdi, Hajiesmaeili, Mohammadreza, Gachkar, Latif, Roshan, Baran, Zangi, Masoud, Mirmomeni, Golshan, Irvani, Seyed S. N., and Alavi Darazam, Ilad

Subjects
COVID-19, CORONAVIRUS diseases, HOSPITAL patients, INTERFERONS, COVID-19 pandemic, COVID-19 treatment
Abstract

Interferons are an essential part of the innate immune system and have antiviral and immunomodulatory functions. We studied the effects of interferon β‐1a on the outcomes of severe cases of coronavirus disease 2019 (COVID‐19). This retrospective study was conducted on hospitalized COVID‐19 patients in Loghman‐Hakim hospital from February 20, 2020 to April 20, 2020, Tehran, Iran. Patients were selected from two groups, the first group received interferon β‐1a in addition to the standard treatment regimen, and the second group received standard care. The clinical progression of two groups during their hospital admission was compared. We studied a total number of 395 hospitalized COVID‐19 patients. Out of this number, 111 patients (33.5%) died (31.3% of the interferon β‐1a group and 34.1% of the control group). The mortality rate indicated no statistically significant difference between groups (p‐value = 0.348), however for patients who were hospitalized for more than a week, the rate of mortality was lower in the interferon β‐1a group (p‐value = 0.014). The median hospital stay was statistically longer for patients treated by interferon β‐1a (p‐value < 0.001). The results of this study showed that interferon β‐1a can improve the outcomes of hospitalized patients with severe COVID‐19, but more adequately‐powered randomized controlled trials should be conducted. Highlights: Interferon‐β‐1a could be effective in treatment of hospitalised COVID‐19. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results